Chihaya Imai

Research output

Research output per year 1997 2022 2023 2024 2024

• 72 Article
• 23 Presentation
• 10 Letter
• 3 Review article
• 2 More
  • 2 Comment/debate

Research output per year

Research output per year

Search results

• 2024

  ALL治療における新たな展開

  今井千速, 2024.

  Research output: Contribution to conference › Presentation

• ALL治療：CCLSG研究からの経験

  今井千速, 2024.

  Research output: Contribution to conference › Presentation

• CAR-T細胞療法の現況と未来

  今井千速, 2024.

  Research output: Contribution to conference › Presentation

• 小児がん医療の最前線

  今井千速, 2024.

  Research output: Contribution to conference › Presentation

• 小児がん経験者がおとなになるために医療者ができる支援とは：学業支援、就業支援から妊孕能保存まで

  今井千速, 2024.

  Research output: Contribution to conference › Presentation

• 急性リンパ性白血病の治療開発

  今井千速, 2024.

  Research output: Contribution to conference › Presentation

• 白血病の新規治療の開発

  今井千速, 2024.

  Research output: Contribution to conference › Presentation
• 2023

  Long-term Follow-up Results of MRD-guided Treatment Protocol for Childhood ALL: CCLSG ALL 2004 study.

  Imai, C., Ikawa, Y., Shimomura, Y. & al., E., 2023.

  Research output: Contribution to conference › Presentation

• 小児がんの治癒を目指して：分子標的薬や細胞製剤を中心に

  今井千速．, 2023.

  Research output: Contribution to conference › Presentation

• 小児がん治療の最前線

  今井千速, 2023.

  Research output: Contribution to conference › Presentation

• 小児がん治療の最近の話題

  今井千速, 2023.

  Research output: Contribution to conference › Presentation

• 小児血液・がん領域の多施設共同研究（Multi-institutional prospective clinical trials in pediatric hematology and oncology）

  今井千速．, 2023.

  Research output: Contribution to conference › Presentation

• 脳腫瘍に対するCAR-T細胞療法

  今井千速．, 2023.

  Research output: Contribution to conference › Presentation

• 難治性肉腫の制圧を目指して　~化学療法からCAR-T/CAR-NK細胞まで~

  今井千速, 2023.

  Research output: Contribution to conference › Presentation
• 2022

  ALLにおけるCAR-T療法：Basic and Beyond

  今井千速, 2022.

  Research output: Contribution to conference › Presentation

• CAR-T細胞療法の歴史と展望．

  今井千速．, 2022.

  Research output: Contribution to conference › Presentation

• Effects of KIR Gene profiles and NKG2D genotype on NK Cell Functions in Healthy individuals

  Hosokai, R. & Imai, C., 2022.

  Research output: Contribution to conference › Presentation

• Generation of chimeric antigen receptor-transduced natural killer cells by using a feeder cell-free system

  Kubo, N., Baba, M., Shin, C., Hosokai, R., Iwabuchi, H., Imamura, M., Saitoh, A. & Imai, C., 2022.

  Research output: Contribution to conference › Presentation

• INDUCTION FAILURE IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN JAPAN: CCLSG/KYCCSG/JACLS/TCCSG JOINT STUDY.

  Imai, C. & al., E., 2022.

  Research output: Contribution to conference › Presentation

• SJMB-96 based high-dose chemotherapy and CSI within 2 weeks after surgery for medulloblastoma; A Case Series from a Single-Center

  Masaru, I., Minori, B., Nobuhiro, K., Changsu, S., Yasushi, K., Ryosuke, H., Haruko, I., Makoto, O., Hiroyuki, I. & Chihaya, I., 2022.

  Research output: Contribution to conference › Presentation

• 小児がんに対するがん免疫療法．

  今井千速．, 2022.

  Research output: Contribution to conference › Presentation

• 小児がん・がん免疫療法．

  今井千速．, 2022.

  Research output: Contribution to conference › Presentation

• 遺伝子改変T細胞／NK細胞によるがん治療の現状と未来．

  今井千速, 2022.

  Research output: Contribution to conference › Presentation